Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tesevatinib in ADPKD
NCT03203642Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tesevatinib in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Sanofi. Started Oct 2017; status: completed.
02
Drugs
tesevatinib
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT03203642.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03203642.